Regeneron stock increased by 19% over the past month, driven by strong third-quarter earnings. But is Gilead the better pick?

Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.

Raj Chovatiya, MD, PhD, MSCI, explains how addressing the most burdensome components of chronic hand eczema can improve ...

For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...

Chronic hand eczema is now considered a “common” skin disease in the United States, according to results from the CHECK study ...

Tens of thousands of people suffering from hand eczema could soon see their painful symptoms disappear, after the NHS today ...

The National Institute for Health and Care Excellence (Nice) has recommended that the cream should be offered to people with ...

From relentless itching and painful flare-ups to sleepless nights and emotional exhaustion, eczema can take a serious toll on both physical and mental well-being. 1,2 For millions of people, it means ...

The publication of this infographic was funded by Leo Pharma A/S and is intended for healthcare professionals only.

A mum has opened up about her daughter’s eczema struggles, saying it was heartbreaking to see her baby’s sheets splattered ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a global leader in medical dermatology, today announced new data from the CHECK (Chronic Hand Eczema epidemiology, Care, and Knowledge) study, ...